Literature DB >> 9719458

p53 may mediate the mdr-1 expression via the WT1 gene in human vincristine-resistant leukemia/lymphoma cell lines.

M Hirose1, Y Kuroda.   

Abstract

To investigate the regulatory mechanism of the expression of the multidrug resistance gene (mdr-1) and the multidrug resistance-associated protein gene (mrp), we investigated if p53, WT1, RB, C-myc, N-myc, cyclin D1, p16INK4 (p16) are involved in the acquirement of multidrug resistance phenotype (MDR) in human vincristine (VCR)-resistant cells of leukemia/lymphoma cell lines. By using RT-PCR, we observed that MDR in VCR-resistant cell lines was mediated by either mdr-1 or mrp genes. In cells that acquired the overexpression of mdr-1, downregulation of p53 and upregulation of WT-1 were observed. In contrast, no constant change of genes was observed in cells that overexpressed mrp. Although the change in the expression level of cyclin D1 and p-16 accompanied the development of VCR resistance, the mRNA of RB, C-myc and N-myc showed no correlation with the degree of VCR resistance or the level of mdr-1 expression. These results may provide a plausible diagnostic marker for determination of drug sensitivity in cancer patients and suggest that p53 may mediate directly or indirectly the expression of mdr-1 via WT1 in VCR-resistant hematologic cell lines.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9719458     DOI: 10.1016/s0304-3835(98)00096-2

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  3 in total

1.  Biology and modulation of multidrug resistance (MDR) in hematological malignancies.

Authors:  Masao Hirose
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

2.  Activation of AMP-activated protein kinase by temozolomide contributes to apoptosis in glioblastoma cells via p53 activation and mTORC1 inhibition.

Authors:  Wen-bin Zhang; Zhuo Wang; Fei Shu; Yong-hua Jin; Hong-yi Liu; Qiu-juan Wang; Yong Yang
Journal:  J Biol Chem       Date:  2010-09-29       Impact factor: 5.157

Review 3.  Pharmacogenetics of anticancer drugs in non-Hodgkin lymphomas.

Authors:  L Loni; M Del Tacca; R Danesi
Journal:  Br J Cancer       Date:  2001-11-16       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.